{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:32:34Z","timestamp":1789903954928,"version":"4.0.1"},"reference-count":49,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"\n OBJECTIVES:<\/jats:title>\n To estimate the rate of admissions to NICUs, as well as infants\u2019 morbidity and neonatal interventions, after exposure to antidepressant drugs in utero.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n Data on pregnancies, deliveries, prescription drug use, and health status of the newborn infants were obtained from the Swedish Medical Birth Register, the Prescribed Drug Register, and the Swedish Neonatal Quality Register. We included 741\u2009040 singletons, born between July 1, 2006, and December 31, 2012. Of the infants, 17\u2009736 (2.4%) had mothers who used selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Infants exposed to an SSRI were compared with nonexposed infants, and infants exposed during late pregnancy were compared with those exposed during early pregnancy only. The results were analyzed with logistic regression analysis.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n After maternal use of an SSRI, 13.7% of the infants were admitted to the NICU compared with 8.2% in the population (adjusted odds ratio: 1.5 [95% confidence interval: 1.4\u20131.5]). The admission rate to the NICU after treatment during late pregnancy was 16.5% compared with 10.8% after treatment during early pregnancy only (adjusted odds ratio: 1.6 [95% confidence interval: 1.5\u20131.8]). Respiratory and central nervous system disorders and hypoglycemia were more common after maternal use of an SSRI. Infants exposed to SSRIs in late pregnancy compared with early pregnancy had a higher risk of persistent pulmonary hypertension (number needed to harm: 285).<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Maternal use of antidepressants during pregnancy was associated with increased neonatal morbidity and a higher rate of admissions to the NICU. The absolute risk for severe disease was low, however.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2016-0181","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T09:07:19Z","timestamp":1477386439000},"source":"Crossref","is-referenced-by-count":73,"title":["Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy"],"prefix":"10.1542","volume":"138","author":[{"given":"Ulrika","family":"N\u00f6rby","sequence":"first","affiliation":[{"name":"Centre of Reproduction Epidemiology, Tornblad Institute, Institution of Clinical Science, Lund University, Lund, Sweden;"},{"name":"Department of E-health and Strategic IT, Health and Medical Care Administration, Stockholm County Council, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Forsberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden;"},{"name":"Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Wide","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden;"},{"name":"Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Sj\u00f6rs","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University, Uppsala, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger","family":"Winbladh","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Education, Karolinska Institutet, Sachs\u2019 Children\u2019s and Youth Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"K\u00e4ll\u00e9n","sequence":"additional","affiliation":[{"name":"Centre of Reproduction Epidemiology, Tornblad Institute, Institution of Clinical Science, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"issue":"14","key":"2021121020325202600_B1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":"Birth outcomes in pregnant women taking fluoxetine.","volume":"335","author":"Chambers","year":"1996","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121020325202600_B2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archpedi.156.11.1129","article-title":"Perinatal outcome following third trimester exposure to paroxetine.","volume":"156","author":"Costei","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2021121020325202600_B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1542\/peds.2006-2133","article-title":"Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.","volume":"119","author":"Ferreira","year":"2007","journal-title":"Pediatrics"},{"issue":"11","key":"2021121020325202600_B4","doi-asserted-by":"crossref","first-page":"e111327","DOI":"10.1371\/journal.pone.0111327","article-title":"Neonatal adaptation in infants prenatally exposed to antidepressants\u2014clinical monitoring using neonatal abstinence score.","volume":"9","author":"Forsberg","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"2021121020325202600_B5","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.4088\/JCP.12r07967","article-title":"The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis.","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2021121020325202600_B6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/JCP.0b013e31826686bc","article-title":"Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors.","volume":"32","author":"Grzeskowiak","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2021121020325202600_B7","author":"Hayes","year":"2012"},{"issue":"4","key":"2021121020325202600_B8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archpedi.158.4.312","article-title":"Neonate characteristics after maternal use of antidepressants in late pregnancy.","volume":"158","author":"K\u00e4ll\u00e9n","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2021121020325202600_B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000350506","article-title":"Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors.","volume":"104","author":"Leibovitch","year":"2013","journal-title":"Neonatology"},{"issue":"2","key":"2021121020325202600_B10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"2021121020325202600_B11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archpediatrics.2009.164","article-title":"Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.","volume":"163","author":"Lund","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"6","key":"2021121020325202600_B12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy.","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2021121020325202600_B13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archpsyc.63.8.898","article-title":"Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.","volume":"63","author":"Oberlander","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2021121020325202600_B14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1192\/bjp.bp.107.037101","article-title":"Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study.","volume":"192","author":"Oberlander","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"3","key":"2021121020325202600_B15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":"Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"2021121020325202600_B16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1176\/appi.ajp.2007.06071172","article-title":"Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.","volume":"164","author":"Suri","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2021121020325202600_B17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajog.2006.02.019","article-title":"Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.","volume":"194","author":"Wen","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2021121020325202600_B18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamapsychiatry.2013.684","article-title":"Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis.","volume":"70","author":"Ross","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"2021121020325202600_B19","author":"Malm"},{"issue":"7","key":"2021121020325202600_B20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11634190-000000000-00000","article-title":"Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in western Australia.","volume":"26","author":"Colvin","year":"2012","journal-title":"CNS Drugs"},{"issue":"10","key":"2021121020325202600_B21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/ph6101221","article-title":"The use of central nervous system active drugs during pregnancy.","volume":"6","author":"K\u00e4ll\u00e9n","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"2021121020325202600_B22","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.293.19.2372","article-title":"Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.","volume":"293","author":"Moses-Kolko","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"2021121020325202600_B23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/OGX.0b013e3181676be8","article-title":"Pharmacological aspects of neonatal antidepressant withdrawal.","volume":"63","author":"Ter Horst","year":"2008","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"2021121020325202600_B24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000356774","article-title":"Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy.","volume":"105","author":"Engelstad","year":"2014","journal-title":"Neonatology"},{"issue":"2","key":"2021121020325202600_B25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/JCP.0b013e3182490eaf","article-title":"Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.","volume":"32","author":"Nordeng","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"2021121020325202600_B26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0447.2009.01490.x","article-title":"A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.","volume":"121","author":"Warburton","year":"2010","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"2021121020325202600_B27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1176\/appi.ajp.2008.08081170","article-title":"Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.","volume":"166","author":"Wisner","year":"2009","journal-title":"Am J Psychiatry"},{"key":"2021121020325202600_B28","doi-asserted-by":"crossref","first-page":"d8012","DOI":"10.1136\/bmj.d8012","article-title":"Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries.","volume":"344","author":"Kieler","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"2021121020325202600_B29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.reprotox.2012.04.015","article-title":"Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review.","volume":"34","author":"\u2019t Jong","year":"2012","journal-title":"Reprod Toxicol"},{"key":"2021121020325202600_B30","doi-asserted-by":"crossref","first-page":"f6932","DOI":"10.1136\/bmj.f6932","article-title":"Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis.","volume":"348","author":"Grigoriadis","year":"2014","journal-title":"BMJ"},{"issue":"7","key":"2021121020325202600_B31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archpsyc.65.7.805","article-title":"Psychiatric disorders in pregnant and postpartum women in the United States.","volume":"65","author":"Vesga-L\u00f3pez","year":"2008","journal-title":"Arch Gen Psychiatry"},{"issue":"17","key":"2021121020325202600_B32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMcp1102730","article-title":"Clinical practice. Depression during pregnancy.","volume":"365","author":"Stewart","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121020325202600_B33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.siny.2013.11.007","article-title":"Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy.","volume":"19","author":"Ornoy","year":"2014","journal-title":"Semin Fetal Neonatal Med"},{"key":"2021121020325202600_B34","author":"National Board of Health and Welfare"},{"key":"2021121020325202600_B35","unstructured":"Centre for Epidemiology. The Swedish Medical Birth Register: a summary of content and quality. Available at: www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/10655\/2003-112-3_20031123.pdf. Accessed February 13, 2015"},{"issue":"7","key":"2021121020325202600_B36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months [published correction appears in","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021121020325202600_B37","unstructured":"Swedish Neonatal Quality Register. Available at: www.medscinet.com\/PNQ\/default.aspx?lang=3. Accessed May 18, 2015"},{"key":"2021121020325202600_B38","first-page":"37","article-title":"A regional perinatal database in southern Sweden\u2014a basis for quality assurance in obstetrics and neonatology.","volume":"164","author":"Molin","year":"1997","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"issue":"3","key":"2021121020325202600_B39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1542\/peds.2012-1999","article-title":"Levels of neonatal care.","volume":"130","author":"American Academy of Pediatrics Committee on Fetus and Newborn","year":"2012","journal-title":"Pediatrics"},{"issue":"7","key":"2021121020325202600_B40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1651-2227.1996.tb14164.x","article-title":"Intrauterine growth curves based on ultrasonically estimated foetal weights.","volume":"85","author":"Mars\u00e1l","year":"1996","journal-title":"Acta Paediatr"},{"issue":"1","key":"2021121020325202600_B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00737-011-0251-1","article-title":"Untreated prenatal maternal depression and the potential risks to offspring: a review.","volume":"15","author":"Davalos","year":"2012","journal-title":"Arch Women Ment Health"},{"issue":"4","key":"2021121020325202600_B42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.infbeh.2010.04.005","article-title":"Prenatal depression effects and interventions: a review.","volume":"33","author":"Field","year":"2010","journal-title":"Infant Behav Dev"},{"issue":"11","key":"2021121020325202600_B43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/070674370404901103","article-title":"Perinatal risks of untreated depression during pregnancy.","volume":"49","author":"Bonari","year":"2004","journal-title":"Can J Psychiatry"},{"issue":"10","key":"2021121020325202600_B44","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.4088\/JCP.14r09035","article-title":"Anxiety disorders during pregnancy: a systematic review.","volume":"75","author":"Goodman","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"2021121020325202600_B45","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamapsychiatry.2016.0934","article-title":"Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta-analysis.","volume":"73","author":"Jarde","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"21","key":"2021121020325202600_B46","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.","volume":"313","author":"Huybrechts","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"2021121020325202600_B47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pcl.2009.04.004","article-title":"Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.","volume":"56","author":"Konduri","year":"2009","journal-title":"Pediatr Clin North Am"},{"issue":"8","key":"2021121020325202600_B48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-011-1021-8","article-title":"Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records.","volume":"67","author":"K\u00e4ll\u00e9n","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2021121020325202600_B49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/AOG.0b013e31818c2a27","article-title":"The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: a systematic review.","volume":"112","author":"Coverdale","year":"2008","journal-title":"Obstet Gynecol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-0181\/1061057\/peds_20160181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-0181\/1061057\/peds_20160181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T06:30:39Z","timestamp":1639204239000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/5\/e20160181\/60334\/Neonatal-Morbidity-After-Maternal-Use-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-0181","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,1]]},"article-number":"e20160181"}}